NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $11.56 -0.20 (-1.70%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.35▼$11.9550-Day Range$8.39▼$11.7652-Week Range$6.01▼$13.14Volume839,988 shsAverage Volume632,532 shsMarket Capitalization$821.34 millionP/E RatioN/ADividend YieldN/APrice Target$14.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Zymeworks alerts: Email Address Zymeworks MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside27.6% Upside$14.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.83 out of 5 starsMedical Sector806th out of 910 stocksPharmaceutical Preparations Industry372nd out of 426 stocks 3.4 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 1 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 1.1 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zymeworks this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to decrease in the coming year, from ($0.85) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesSeptember 3, 2024 | globenewswire.comZymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)August 30, 2024 | uk.finance.yahoo.comZymeworks Inc (ZA8.BE)September 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 30, 2024 | sg.finance.yahoo.comZymeworks Inc. (ZA8.F)August 26, 2024 | benzinga.comZymeworks (NASDAQ:ZYME) Stock Quotes, Forecast and News SummaryAugust 22, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesAugust 13, 2024 | markets.businessinsider.comBuy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital AllocationAugust 7, 2024 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) ForecastsSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 4, 2024 | finance.yahoo.comZymeworks Inc. (NASDAQ:ZYME) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAugust 1, 2024 | marketwatch.comZymeworks Board Authorizes $60M Share Repurchase ProgramAugust 1, 2024 | finance.yahoo.comZymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | seekingalpha.comZymeworks Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 1, 2024 | globenewswire.comZymeworks Announces Share Repurchase Program of up to $60 Million of its Common StockAugust 1, 2024 | markets.businessinsider.comZymeworks earnings preview: what to expectJuly 30, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesJuly 25, 2024 | globenewswire.comZymeworks Appoints Leone Patterson as Chief Business and Financial OfficerJuly 22, 2024 | markets.businessinsider.comFDA Clears IND Application Of Zymeworks For ZW191See More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$14.75 High Stock Price Target$21.00 Low Stock Price Target$10.00 Potential Upside/Downside+27.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-179.42% Pretax Margin-184.96% Return on Equity-21.97% Return on Assets-17.26% Debt Debt-to-Equity RatioN/A Current Ratio7.01 Quick Ratio7.01 Sales & Book Value Annual Sales$76.01 million Price / Sales10.81 Cash FlowN/A Price / Cash FlowN/A Book Value$5.72 per share Price / Book2.02Miscellaneous Outstanding Shares71,050,000Free Float69,842,000Market Cap$821.34 million OptionableOptionable Beta1.19 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)CEO & Chairman of the Board Comp: $1.04MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $682.22kDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Comp: $872.67kMr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorVice President of Human Resources & DEIDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia PacificMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNHUTCHMEDNASDAQ:HCMRhythm PharmaceuticalsNASDAQ:RYTMMoonLake ImmunotherapeuticsNASDAQ:MLTXMerusNASDAQ:MRUSView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 197,760 shares on 8/19/2024Ownership: 0.280%Perceptive Advisors LLCBought 592,904 shares on 8/16/2024Ownership: 2.347%Susquehanna Fundamental Investments LLCBought 4,444 shares on 8/15/2024Ownership: 0.084%Susquehanna Portfolio Strategies LLCSold 2,526 shares on 8/15/2024Ownership: 0.035%The Manufacturers Life Insurance Company Bought 2,653 shares on 8/15/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $10.39 on January 1st, 2024. Since then, ZYME stock has increased by 11.3% and is now trading at $11.56. View the best growth stocks for 2024 here. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) posted its earnings results on Thursday, August, 1st. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm had revenue of $19.24 million for the quarter, compared to analysts' expectations of $23.16 million. Zymeworks had a negative trailing twelve-month return on equity of 21.97% and a negative net margin of 179.42%. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Top institutional shareholders of Zymeworks include Rubric Capital Management LP (5.54%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.73%), Perceptive Advisors LLC (2.35%) and Dimensional Fund Advisors LP (1.01%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson, Paul Andrew Moore and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL) and Alibaba Group (BABA). This page (NYSE:ZYME) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
